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Abstract 
Recent chemotherapies for skin metastases from breast cancer have shown to be 
effective for regression, disappearance, and favorable quality of life. We describe the 
case of a 76-year-old male showing transient effectiveness with an oral 5-fluorouracil 
derivative, S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate), for 
epirubicin, cyclophosphamide and paclitaxel refractory skin metastases from possible 
occult breast cancer. The male patient was initially diagnosed as having lymph node 
metastases in the left axilla as possible occult breast cancer. The skin metastases 
developed after chemotherapy with a combination of epirubicin and cyclophosphamide, 
subsequent chemotherapy with paclitaxel, and radiotherapy. Chemotherapy with 
paclitaxel was resumed for skin metastases, but it was not effective. Alternative 
chemotherapy with the oral agent S-1 was administered. The skin metastases completely 
disappeared after the second course, but recurred at the end of the third course. This 
case suggests that S-1 may be a candidate for chemotherapy for skin metastases from 
occult breast cancer in males. 
 
Introduction 
Breast cancer in a male is very rare, comprising less than 1% of all breast cancers and 
less than 1% of all cancers in men [1, 2]. The occurrence of occult breast cancer in a male  
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is even rarer, although some cases have been reported [3, 4]. Here, we report a male 
having epirubicin, cyclophosphamide and paclitaxel refractory skin metastases from 
possible occult breast cancer. The skin metastases transiently disappeared completely 
following a chemotherapy with an oral 5-fluorouracil (5-FU) derivative, S-1 (tegafur, 5-
chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate; Taiho Pharmaceutical 
Co. Ltd., Tokyo, Japan). 
Case Report 
A 76-year-old Japanese man presented to our department with asymptomatic eruptions. The initial 
examination revealed asymptomatic erythematous patches and linear macules, which were gradually 
increasing in size and number on the left chest and back (fig. 1a). The patient had had an edematous 
swelling on the left arm and a palpable lymph node on the left axilla 1.5 years earlier. Lymph nodes, 
except the left axilla, had not been palpable. A chest X-ray had been clear. A positron emission 
tomography (PET)/computed tomography (CT)-scan of the entire body had shown only enlarged 
lymph nodes in the left axilla and had not depicted any other lesions. The lymph nodes in the left axilla 
had been excised surgically. Tumor cells were detected in 9 out of 30 lymph nodes. 
Immunohistochemical staining showed positive reaction to gross cystic disease fluid protein-15 
(GCDFP-15) and mammaglobin, and negative reaction to human epithelial growth factor receptor type 
2 (HER2), estrogen receptor (ER), and progesterone receptor (PgR). The patient had been diagnosed as 
having lymph node metastases from possible occult breast cancer. He had received chemotherapy 
consisting of epirubicin 25 mg/m
2 and cyclophosphamide 100 mg/body once a week for 18 courses, 
following chemotherapy with paclitaxel 80 mg/m
2 once a week for 14 courses, and then he had been 
given radiotherapy consisting of electron radiation, 2 Gy per irradiation (total 30 times, 60 Gy), on the 
left upper chest, axilla and back. 
Histopathological examination of a biopsy specimen revealed an extensive invasion of the dermal 
lymphatics by groups and cords of tumor cells (fig. 1b). The cells were similar to those in the lymph 
nodes in the left axilla. Morphologically, they were irregular in size and shape, with large, pleomorphic 
and hyperchromatic nuclei (fig. 1d). Immunohistochemical staining showed positive reaction to 
GCDFP-15, and negative reaction to mammaglobin, HER2, ER and PgR. The erythematous patches and 
linear macules were diagnosed to be skin metastases from possible occult breast cancer. Systemic 
examination showed no enlarged lymph nodes or focal lesions except skin involvement.  
Chemotherapy with paclitaxel was resumed. The regimen was the same as in the previous treatment 
(80 mg/m
2 once a week). At the end of the 5 courses, we concluded that the chemotherapy was not 
effective for the metastatic cancer. The erythematous patches and linear macules grew into a painful 
large dark reddish patch and necrotic nodules (fig. 1c). 
An alternative chemotherapy with S-1 (tegafur 120 mg, CDHP 34.8 mg, potassium oxonate 117.6 
mg) was administered orally. A regime was established consisting of oral administration of S-1 for 28 
days followed by an intermission of 14 days. Complete disappearance was achieved, when 2 courses 
were given. The lesion showed pigmented macules and an ulcer, 40 × 30 mm in size, with no pain (fig. 
2a). A spindle biopsy from the border of the ulcerated lesion was taken for histopathological evaluation. 
The specimen revealed a massive infiltration of inflammatory cells in the dermis, dilated vessels, and 
extravessel erythrocytes (fig. 2b). The infiltrated cells were intermingled with plasma cells, lymphocytes 
and histiocytes (fig. 2c). 
However, 2 elastic hard papules, 5 × 5 mm in size, developed on the previously affected lesion after 
the end of the third course of the S-1 administration (fig. 3a). A biopsied specimen from a papule 
showed tumor cells that were morphologically irregular in size and shape with large, pleomorphic and 
hyperchromatic nuclei (fig. 3b, c). Immunohistochemical staining showed positive reaction to GCDFP-
15 and negative reaction to mammaglobin, HER2, ER and PgR.  
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The skin lesion was diagnosed as skin metastases from possible occult breast cancer. 
Occult breast cancer commonly presents lymph node metastasis of the axilla, 
supraclavicular fossa and infraclavicular fossa as first manifestation [4, 5]. One differential 
diagnosis is primary carcinoma of an accessory mammary gland. The histopathological 
specimen is characterized by the presence of sweat glands, sebaceous glands, and 
connective tissue [6]. 
Chemotherapy consisting of epirubicin and cyclophosphamide is commonly given as 
the first-line therapy for metastatic breast cancer. Taxanes, such as paclitaxel, are used in 
early-stage breast cancer and in first-line therapy for metastatic breast cancer [7]. 
Treatment of taxane-refractory disease is challenging and newer agents are being 
developed for clinical application [7]. S-1 is an oral fluoropyrimidine formulation that 
combines tegafur, CDHP, and potassium oxonate in a molar ratio of 1:0.4:1 [8]. CDHP 
inhibits an enzyme that metabolites 5-FU, dihydropyrimidine dehydrogenase [9]. 
Therefore, high 5-FU concentrations are maintained, and S-1 may be effective in patients 
who do not respond to other fluoropyrimidine agents [9]. Potassium oxonate can reduce 
gastrointestinal toxicities, which are the main adverse events of 5-FU agents [9]. Single 
agent S-1 has demonstrated marked activity against a broad array of solid tumors, 
including breast, gastric, colorectal, cervical, pancreatic, and lung cancers [8]. The 
strategy for treating metastatic breast cancer is to maintain favorable quality of life and to 
improve survival [9]. S-1 may be a valuable agent for metastatic and recurrent breast 
cancer because it shows clinical efficacy and mild toxicity and can be given orally [9]. A 
randomized controlled trial is currently comparing S-1 with standard chemotherapies, 
such as taxanes, in women with metastatic or recurrent breast cancer [10]. In the present 
case, temporal complete disappearance was achieved. We believe that the administration 
of S-1 temporarily kept the patient in a comfortable condition and improved the period of 
survival. 
In summary, we described the case of a male patient with skin metastases from possible 
occult breast cancer. S-1 may be a candidate for chemotherapy for skin metastases from 
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Fig. 1. a Clinical image of erythematous patches and linear macules on the left chest and back. b, d A 
biopsied specimen from an erythematous linear macule. HE, original magnification, ×100 (b), ×400 (d). 
c Clinical image of a large dark reddish patch with necrotic nodules after 5 courses of resumed 
chemotherapy with paclitaxel. 
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Fig. 2. a Clinical image of complete disappearance of the metastatic skin lesion after 2 courses of S-1 
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Fig. 3. a Clinical image of 2 elastic hard papules, 5 × 5 mm in size, that recurred after the end of the 
third course of the S-1 administration. b, c A biopsied specimen from a papule. HE, original 
magnification, ×100 (b), ×400 (c). 
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